Jared Whitlock
Reporter
Phone: 858-634-4636 Extension: 3130
Recent Stories
Life Science Funding Shows Increase in Most Rounds
Financing rounds since 2013 have grown larger in San Diego life sciences. A look at annual median deal size shows an increase, from early-stage seed financing to Series A, C and D rounds. Only Series B rounds have remained flat in recent years.
Aristea Therapeutics Launches with $15M Round
Aristea Therapeutics emerged Dec. 18 with a $15 million series A round and mission revolving around inflammatory diseases.
Evofem’s Stock Rises on Positive Late-Stage Trial Data
Shares of Evofem rose on Dec. 17 after the company reported that its birth control gel worked as intended in late-stage clinical trials.
Former Ignyta Talent Launch Erasca with $42M Round
Serial biotech entrepreneur Jonathan Lim is back at it.
Aethlon Medical Appoints Interim CEO
Aethlon Medical, a San Diego company, named Timothy Rodell as interim CEO, it was announced Dec. 13.
Local Strengths Like Genetics, Big Data and Talent Power Agbio Scene
Technology, Talent Keep Area’s Agriculture Growing Strong
Decades ago on North County farms, the Ecke family turned the poinsettia into a top-selling Christmas plant. From former Ecke land, Cibus again wants to put the region on the map.
Medical Tourism Still Needs A Shot in the Arm
A medical tourism campaign touting San Diego’s hospitals, genomics companies and sunny weather is trying to find its groove.
Epipen Alternative to Bring Good News to Price Sensitive Users
Adamis Pharmaceuticals’ epipen alternative will launch nationally in the first quarter of next year, the company said in a recent update.
Neurocrine’s Tourette Syndrome Drug Misses Primary Goal
San Diego-based Neurocrine’s drug for Tourette syndrome failed to meet its primary goal in a mid-stage clinical trial, the company reported Dec. 12.
Following the Local Biotech VC Funding Trail
The San Diego Business Journal frequently chronicles local funding rounds and the big dreams that accompany them. But what about the largest venture capital sources locally?
